A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.

Administration of a second Typhax dose on Day 28 did not result in a measurable increase in GMT at Day 42 or Day 180 at any dose level, except for the 10.0 μg Typhax group, where the titer increased from 171 to 318, however this increase did not reach statistical significance ( Table 4 and Fig 2 ).

also in 111,027 other papers